3-甲氧基-6-甲基-1,2-苯二胺 | 101251-28-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 3-甲氧基-6-甲基-1,2-苯二胺
• 英文名称: 3-methyl-6-methoxy-1,2-diaminobenzene
• 英文别名: 3-methoxy-6-methyl-1,2-phenylenediamine；2,3-diamino-4-methoxytoluene；3-methoxy-6-methyl-o-phenylenediamine；3-Methoxy-6-methyl-o-phenylendiamin；2.3-Diamino-4-methoxy-toluol；2.3-Diamino-4-methoxy-1-methyl-benzol；3-Methoxy-6-methylbenzene-1,2-diamine
• CAS: 101251-28-9
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: JBHXVPWMLQFNPL-UHFFFAOYSA-N

物化性质

• 沸点：
  296.9±35.0 °C(Predicted)
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  61.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-甲氧基-6-甲基-1,2-苯二胺 在 氢溴酸 作用下， 反应 5.0h， 生成 2-(4-chlorobenzyl)-7-methyl-1H-benzimidazol-4-ol hydrobromide
  参考文献：
  名称：

  Novel 1H-benzimidazol-4-ols with potent 5-lipoxygenase inhibitory activity

  摘要：

  The synthesis and structure--activity profile of 2-substituted benzimidazol-4-ols as inhibitors of cell-free RBL-1 5-lipoxygenase are discussed, and their potency is compared with that of the standard inhibitors phenidone, AA 861, BW 755C, and nordihydroguaiaretic acid. In contrast to the standard compounds, most did not inhibit the release of slow-reacting substance of anaphylaxis (SRS-A) in vivo when administered at 200 microM ip to rats subjected to peritoneal anaphylaxis, although five compounds containing a methoxylated benzyl group (compounds 36, 39, 42, and 43) or hydroxylated benzyl group (41) showed similar activity to that of phenidone, nordihydroguaiaretic acid, and AA 861. Of the many compounds tested, two, 5-tert-butyl-7-methyl-2-(trifluoromethyl)-1H-benzimidazol-4-ol (57) and 2-(4-methoxybenzyl)-7-methyl-1H-benzimidazol-4-ol (36), like dexamethasone, inhibited monocyte accumulation in a pleural exudate model of inflammation. Standard lipoxygenase inhibitors such as phenidone, BW 755C, and AA 861 were inactive in this system.

  DOI：

  10.1021/jm00395a007
• 作为产物：
  描述：

  4-甲基-3-硝基苯甲醚 在 盐酸 、 tin 、 硫酸 、 硝酸 、 溶剂黄146 作用下， 生成 3-甲氧基-6-甲基-1,2-苯二胺
  参考文献：
  名称：

  Kaufler; Wenzel, Chemische Berichte, 1901, vol. 34, p. 2239

  摘要：

  DOI：

文献信息

• [EN] BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES<br/>[FR] DÉRIVÉS PONTÉS DU TÉTRAHYDRONAPHTALÈNE
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2010046855A1

  公开（公告）日：2010-04-29

  The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, A, B, W and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.

  这项发明涉及式（I）的化合物，其中R1、R2、R3、R4、A、B、W和n如描述中所定义，并且涉及这些化合物的药用盐。这些化合物可用作钙通道阻滞剂。
• TUMOR TARGETED DRUG COMBRETASTATIN A4 DERIVATIVE
  申请人：Wang Yong

  公开号：US20140128384A1

  公开（公告）日：2014-05-08

  The present invention relates to imidazole, oxazole and thiazole derivatives of tumor-targeted drug combretastatin A4, and phosphate esters, sulfonate esters or pharmaceutically acceptable salts, glycoside derivatives, solvates thereof, wherein the A-ring comprises a 3,5-dimethoxyphenyl group having a substituent at the 4-position. The pharmacological activity assays have demonstrated that the compounds of the present invention have good in vitro anti-tumor activity and excellent tubulin inhibitory effect.

  本发明涉及肿瘤靶向药物康柏他丁A4的咪唑、噁唑和噻唑衍生物，以及磷酸酯、磺酸酯或药用可接受的盐、糖苷衍生物、其溶剂合物，其中A环包括在4位有取代基的3,5-二甲氧基苯基基团。药理活性测定表明，本发明的化合物在体外具有良好的抗肿瘤活性和优秀的微管抑制作用。
• Benzimidazoles as 5-lipoxygenase inhibitors
  申请人：Beecham Group PLC

  公开号：US04925853A1

  公开（公告）日：1990-05-15

  Compounds of the general formula I ##STR1## or pharmaceutically acceptable salts or solvates thereof, in which R.sup.1 represents hydrogen or a lower alkyl group, R.sub.2 represents hydrogen, a lower alkyl group, or ##STR2## R.sup.3 represents hydrogen, a lower alkyl group, or ##STR3## R.sup.4 represents hydrogen or a lower alkyl group, R.sup.5 represents hydrogen or a lower alkyl group, R.sup.6 represents hydrogen, a lower alkyl, a substituted or unsubstituted aryl group, or --COOR.sup.15, R.sup.7 represents hydrogen, halogen or lower alkyl, R.sup.8 represents a lower alkyl or a substituted or unsubstituted carbocyclic aryl group, R.sup.15 represents hydrogen or a lower alkyl, and n is 0 to 8, n being 0 when R.sup.6 represents lower alkyl, are disclosed as an active therapeutic substances for the treatment of inflammatory conditions, allergic conditions and disorders related to loss of gastro-intestinal integrity.

  通式I ##STR1## 或其药学上可接受的盐或溶剂合物，其中R.sup.1代表氢或低碳基，R.sub.2代表氢，低碳基，或##STR2##，R.sup.3代表氢，低碳基，或##STR3##，R.sup.4代表氢或低碳基，R.sup.5代表氢或低碳基，R.sup.6代表氢，低碳基，取代或未取代的芳基基团，或--COOR.sup.15，R.sup.7代表氢，卤素或低碳基，R.sup.8代表低碳基或取代或未取代的碳环芳基基团，R.sup.15代表氢或低碳基，n为0至8，当R.sup.6代表低碳基时，n为0。该化合物被披露为治疗炎症状况，过敏症状和与胃肠道完整性丧失有关的疾病的有效治疗物质。
• BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES
  申请人：Hilpert Kurt

  公开号：US20110263648A1

  公开（公告）日：2011-10-27

  The invention relates to compounds of formula (I) wherein R 1 , R 2 , R 3 , R 4 , A, B, W and n are as defined in the description, and to pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.

  本发明涉及式(I)的化合物，其中R1、R2、R3、R4、A、B、W和n如描述中所定义，并涉及这些化合物的药学上可接受的盐。这些化合物可用作钙通道阻滞剂。
• BRIDGED SIX-MEMBERED RING COMPOUNDS
  申请人：Hilpert Kurt

  公开号：US20100130545A1

  公开（公告）日：2010-05-27

  The invention relates to compounds of formula (I), wherein R 1 , R 2 , R 1a , R 2a , R 3 , R 4 , A, B, X, W and n are as defined in the description, and pharmaceutically acceptable salts of such compounds. These compounds are useful as calcium channel blockers.

  本发明涉及式(I)的化合物，其中R1、R2、R1a、R2a、R3、R4、A、B、X、W和n如描述中所定义，并且这些化合物的药学上可接受的盐。这些化合物可用作钙通道阻滞剂。